New insider activity at Exelixis ( (EXEL) ) has taken place on May 8, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Recent insider activity at Exelixis has seen three directors cash in significant holdings. Director George Poste led the way by selling 60,000 shares of Exelixis stock in a transaction valued at $2,742,600. Director Maria Freire followed with the sale of 20,634 shares, bringing in $949,164. Additionally, Director Mary Beckerle sold 7,712 shares for a total of $373,646. These combined insider sales underscore notable share disposals by key members of Exelixis’s board.
Recent Updates on EXEL stock
Exelixis shares reacted to its Q1 earnings call, where strong CABOMETYX-driven revenue growth, robust profitability, large cash reserves and sizeable buybacks underscored solid execution, but management also highlighted rising gross-to-net pressures, a one-time tax spike and growing operating complexity from its expanding pipeline. Analysts reassessed targets mainly on the balance between this durable cabo franchise and execution risk around ZANZA, including multiple pivotal STELLAR trials and the LITESPARK-034 collaboration with Merck, which could reshape RCC standards if successful but introduces substantial clinical and regulatory uncertainty.
Spark’s Take on EXEL Stock
According to Spark, TipRanks’ AI Analyst, EXEL is a Outperform.
EXEL scores well on financial performance (rapid revenue scaling, improved profitability, strong cash generation, and low leverage). Earnings-call takeaways add support via reiterated guidance, strong CABOMETYX commercial momentum, and aggressive buybacks, partially offset by gross-to-net and pipeline/readout uncertainty. Technicals are positive on trend (price above key averages) but mixed on near-term momentum, while valuation looks reasonable with a ~13.5 P/E and no dividend data.
To see Spark’s full report on EXEL stock, click here.
More about Exelixis
YTD Price Performance: 5.43%
Average Trading Volume: 2,825,981
Technical Sentiment Signal: Buy
Current Market Cap: $11.62B